NCT01134393 - TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch | Biotech Hunter

Enrollment

502

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2011

Conditions

Hypertension

Interventions

DRUG

telmisartan/amlodipine

start low dose and uptitrate to high dose on the basis of BP goal

Trial Locations (47)

Unknown

1235.33.49010 Boehringer Ingelheim Investigational Site, Berlin

1235.33.49002 Boehringer Ingelheim Investigational Site, Frankfurt

1235.33.49007 Boehringer Ingelheim Investigational Site, Haag

1235.33.49003 Boehringer Ingelheim Investigational Site, Heidelberg

1235.33.49005 Boehringer Ingelheim Investigational Site, Künzing

1235.33.49008 Boehringer Ingelheim Investigational Site, Nuremberg

1235.33.49009 Boehringer Ingelheim Investigational Site, Rednitzhembach

1235.33.49006 Boehringer Ingelheim Investigational Site, Rodgau-Dudenhofen

1235.33.49004 Boehringer Ingelheim Investigational Site, Unterschneidheim

1235.33.49001 Boehringer Ingelheim Investigational Site, Westerkappeln

1235.33.39009 Boehringer Ingelheim Investigational Site, Arezzo

1235.33.39002 Boehringer Ingelheim Investigational Site, Bologna

1235.33.39004 Boehringer Ingelheim Investigational Site, Ferrara

1235.33.39006 Boehringer Ingelheim Investigational Site, L’Aquila

1235.33.39007 Boehringer Ingelheim Investigational Site, Napoli

1235.33.39001 Boehringer Ingelheim Investigational Site, Pisa

1235.33.39008 Boehringer Ingelheim Investigational Site, Roma

1235.33.39005 Boehringer Ingelheim Investigational Site, Stradella (PV)

1235.33.52004 Boehringer Ingelheim Investigational Site, Aguascalientes

1235.33.52002 Boehringer Ingelheim Investigational Site, Durango

1235.33.52001 Boehringer Ingelheim Investigational Site, Guadalajara

1235.33.52003 Boehringer Ingelheim Investigational Site, Guadalajara

1235.33.52007 Boehringer Ingelheim Investigational Site, Guadalajara

1235.33.52006 Boehringer Ingelheim Investigational Site, México

1235.33.52009 Boehringer Ingelheim Investigational Site, México

1235.33.52008 Boehringer Ingelheim Investigational Site, Monterrey

1235.33.31007 Boehringer Ingelheim Investigational Site, 's-Hertogenbosch

1235.33.31009 Boehringer Ingelheim Investigational Site, Almere Stad

1235.33.31005 Boehringer Ingelheim Investigational Site, Beek en Donk

1235.33.31002 Boehringer Ingelheim Investigational Site, Beerzerveld

1235.33.31008 Boehringer Ingelheim Investigational Site, Ermelo

1235.33.31006 Boehringer Ingelheim Investigational Site, Lichtenvoorde

1235.33.31001 Boehringer Ingelheim Investigational Site, Musselkanaal

1235.33.31004 Boehringer Ingelheim Investigational Site, Nijverdal

1235.33.31003 Boehringer Ingelheim Investigational Site, Wildervank

1235.33.48005 Boehringer Ingelheim Investigational Site, Chorzów

1235.33.48002 Boehringer Ingelheim Investigational Site, Częstochowa

1235.33.48003 Boehringer Ingelheim Investigational Site, Częstochowa

1235.33.48010 Boehringer Ingelheim Investigational Site, Dąbrowa Górnicza

1235.33.48006 Boehringer Ingelheim Investigational Site, Grodzisk Mazowiecki

1235.33.48013 Boehringer Ingelheim Investigational Site, Oświęcim

1235.33.48008 Boehringer Ingelheim Investigational Site, Piotrkow Trybunalski

1235.33.48004 Boehringer Ingelheim Investigational Site, Poznan

1235.33.48001 Boehringer Ingelheim Investigational Site, Tychy

1235.33.48009 Boehringer Ingelheim Investigational Site, Tychy

1235.33.48011 Boehringer Ingelheim Investigational Site, Warsaw

1235.33.48007 Boehringer Ingelheim Investigational Site, Wroclaw